glp-1 drugs for inflammation Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications Glucagon-like peptide-1: a multi-faceted anti-inflammatory
Description
The established and emerging roles of GLP-1RAs critically examine their efficacy, safety, financial burden, and disparities in access, limitations, and prospects
The key difference from CagriSema (which combines separate cagrilintide and semaglutide) is that amycretin integrates both GLP-1 and amylin agonism into a single molecule, enabling both subcutaneous and oral formulations
Available: [12] H
In a recent study published in the Journal of Clinical Investigation , researchers reviewed the anti-inflammatory effects and mechanisms of glucagon-like peptide 1 (GLP-1)-based therapies
doi: 10.1038/s41574-019-0176-8 [DOI] [PubMed] [Google Scholar] 3.Rubino F, Puhl RM, Cummings DE, et al
